CRINETICS DATA AT ENDO HIGHLIGHTS PROGRESS TOWARD VISION OF BUILDING THE PREMIER ENDOCRINE-FOCUSED PHARMACEUTICAL COMPANY
“This year’s Endocrine Society meeting represents a major milestone for Crinetics as we present initial findings from two clinical studies of atumelnant (CRN04894), our investigational, once-daily oral ACTH receptor antagonist, in development for the treatment of people with classic congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, in addition to presentations featuring data from the acromegaly Phase 3 trials of our lead development candidate, paltusotine.”
– Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics
Once Daily Oral Atumelnant (CRN04894) Induces Rapid and Profound Reductions of Androstenedione and 17-hydroxyprogesterone in Participants with Classical Congenital Adrenal Hyperplasia: Initial Results from a 12-Week, Phase 2, Open-Label Study
Date/Time: June 3rd from 12:00 – 1:30 pm ET
Location: Session P108 – Late-Breaking Poster Presentations – ENDOExpo PosterArea – BCEC
Atumelnant (CRN04894) Induces Rapid And Sustained Reductions In Serum And Urine Cortisol In Patients With ACTH-dependent Cushing Syndrome During A Phase 1b/2a, Single Center, 10-day, Inpatient, Open-label Study
Date/Time: June 3rd from 12:00 – 1:30 pm ET
Location: Session P108 – Late-Breaking Poster Presentations – ENDOExpo PosterArea – BCEC
Efficacy and Safety of Once-Daily Oral Paltusotine in Medically Untreated Patients With Acromegaly: Results from the Phase 3, Randomized, Placebo-Controlled PATHFNDR-2 Study
Date/Time: June 3rd from 12:00 – 1:30 pm ET
Location: Session P108 – Late-Breaking Poster Presentations – ENDOExpo PosterArea – BCEC
Use of the Acromegaly Symptom Diary (ASD) in a Phase 3, Placebo-Controlled Study of Once-Daily, Oral Paltusotine in Patients With Acromegaly Switched From Injected Octreotide or Lanreotide
Date/Time: June 3rd from 12:00pm – 1:30 pm ET
Location: Neuroendocrinology and Pituitary: Pituitary Tumors IV – ENDOExpo PosterArea – BCEC
Long-Term Safety and Efficacy of Once-Daily Oral Paltusotine in the Treatment of Patients With Acromegaly: Update From ACROBAT Advance
Date/Time: June 3rd from 12:00 – 1:30 pm ET
Location: Session P108 – Late-Breaking Poster Presentations – ENDOExpo PosterArea – BCEC
Paltusotine Science & Innovation Theater
Date/Time: June 1 | 3:15-4:15 PM ET
Location: Theater #2
Data from the PATHFNDR program will be featured in a Science and Innovation Theater led by Dr. Kevin C.J. Yuen, of the Barrow Neurological Institute, on Saturday, June 1, 2024, titled “Paltusotine: A Novel, Investigational Oral Small Molecule Somatostatin Receptor Ligand for Acromegaly.”
2nd Annual Patient Advocacy Leadership Workshop: Empowering Change
On June 3rd, members of Crinetics’ leadership will host a workshop with leaders from patient advocacy organizations to discuss what patient empowerment means to their communities. This year’s event will focus on critical areas in need of self-advocacy resources and ways that Crinetics can best support patient empowerment efforts.
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
Recent News
Interested in Opportunities to Join Our Team?
Our passion for our work runs deep. Crinetics was founded by a team of scientists with a track record of drug discovery and development and the collaboration, curiosity and empathy that fueled our beginning, and drives our team today. Crinetics is a destination for thinkers, doers, and creators, united in a pursuit of innovation in the treatment of endocrine-related conditions.
Connect With Us
Please complete this form to be contacted directly by a member of our medical affairs team.